Melanotan I vs NA-Semax Amidate
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →NA-Semax Amidate
NA-Semax Amidate (N-Acetyl Semax Amidate) is a modified version of Semax with enhanced stability and potency. Also known as NASA, it provides stronger and longer-lasting nootropic effects than standard Semax.
Full details →Side-by-Side Comparison
| Aspect | Melanotan I | NA-Semax Amidate |
|---|---|---|
| Dose Range | 250 mcg–500 mcg | 300 mcg–600 mcg |
| Frequency | 1x daily | 2x daily |
| Cycle Length | 1–4 weeks | 2–4 weeks |
| Route | subcutaneous | intranasal |
| Mechanism | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. | Maintains Semax's core actions on BDNF, NGF, and monoamine systems with improved pharmacokinetics. The modifications enhance CNS penetration and extend duration of action. |
| Typical Dosage | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. | Intranasal: 100-600mcg 1-2 times daily. Start with lower doses as it's more potent than standard Semax. |
| Administration | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. | Intranasal spray is most common. Can be used sublingually. More stable than standard Semax in solution. |
| Side Effects | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. | May cause irritability, hair shedding (rare), or overstimulation at high doses. Generally well-tolerated. |
| Best For |
Key Differences
Unique to Melanotan I:
Unique to NA-Semax Amidate:
Key Studies
Melanotan I
- Use of melanotan I and II in the general population.
BMJ (Clinical research ed.), 2009
- Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.
Pharmaceutical research, 2000
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
Pharmaceutical biotechnology, 1998
Ready to Learn More?
Looking for trusted sources?